Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Anthem says COVID-19 costs could rise in coming quarters from variants

Stock MarketsJul 21, 2021 11:38AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The office building of health insurer Anthem is seen in Los Angeles, California February 5, 2015. REUTERS/Gus Ruelas

By Manojna Maddipatla

(Reuters) -U.S. health insurer Anthem on Wednesday warned of potentially higher COVID-19 costs in the second half of the year in the light of new coronavirus variants coupled with a slowing vaccination rate in the country.

The company's comments come after lower-than-expected medical costs helped it beat Wall Street estimates for second-quarter profit and raise its adjusted earnings forecast for the year by 40 cents.

Health insurers have been conservative in their 2021 outlooks as they expect fluctuations in medical costs due to the impact of virus variants and new outbreaks in some parts of the country, especially in areas with low vaccination rates.

"There's still a considerable amount of uncertainty surrounding COVID in the back half of the year and so we obviously want to maintain a prudent, if not cautious, posture," Anthem Chief Financial Officer John Gallina said.

The company backed its expectations of $600 million in COVID-19 costs in 2021.

Last week, larger rival UnitedHealth (NYSE:UNH) said it still expects a $1.80 per share hit to this year's profit due to COVID-19 treatment and testing costs, even as it raised full-year earnings target.

Health insurers seem to be adding in some additional earnings cushion for the second half by not raising by the full amount of the second-quarter beat, given the potential for medical costs to continue to rise, Stephens analyst Scott Fidel said.

Anthem on Wednesday became the latest large U.S. health insurer after UnitedHealth to say it was still watching out for additional guidance on Biogen Inc (NASDAQ:BIIB)'s newly approved $56,000 Alzheimer's drug Aduhelm.

The U.S. government's Medicare program and private health insurers, which sell Medicare Advantage plans for those over 65 years of age, will be bearing most of the drug's cost and delayed decision on its coverage could slow its uptake by patients.

Anthem says COVID-19 costs could rise in coming quarters from variants
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email